Attune Pharmaceuticals Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$23.3M
- Investors
-
7
Attune Pharmaceuticals General Information
Description
Developer of orally administered small molecule therapeutics designed for the treatment of rare diseases. The company develops therapeutics, heterocyclic derivative compounds, and pharmaceutical compositions used to cure hereditary angioedema and other diseases, enabling clinicians to treat rare medical conditions.
Contact Information
Website
www.attunepharma.comCorporate Office
- 250 West 55th Street
- 34th Floor
- New York, NY 10019
- United States
Corporate Office
- 250 West 55th Street
- 34th Floor
- New York, NY 10019
- United States
Attune Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 23-Jan-2019 | $23.3M | 000.00 | 00000 | Completed | Clinical Trials - Phase 1 |
| 1. Early Stage VC (Series A) | 00.000 | 00.000 | 000.00 | Completed | Startup |
Attune Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.000 |
Attune Pharmaceuticals Comparisons
Industry
Financing
Details
000000
000000
Attune Pharmaceuticals Competitors (58)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Epirium Bio | Venture Capital-Backed | San Diego, CA | 00 | 000.00 | 00000000000 | 000.00 |
| Morphic Therapeutic | Formerly VC-backed | Waltham, MA | 000 | 00000 | 000000&0 | 00000 |
| Cour | Venture Capital-Backed | Skokie, IL | 00 | 00000 | 00000000000 | 00000 |
| Immusoft | Venture Capital-Backed | Seattle, WA | 00 | 000.00 | 00000000000 | 000.00 |
| JW Therapeutics | Formerly VC-backed | Shanghai, China | 000 | 00000 | 00000000 | 00000 |
Attune Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Attune Pharmaceuticals Patents
Attune Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3758702-A1 | Treatment of hereditary angioedema | Inactive | 28-Feb-2018 | 00000000 | |
| US-20200405708-A1 | Treatment of hereditary angioedema | Inactive | 28-Feb-2018 | 00000000 | |
| CA-3092538-A1 | Treatment of hereditary angioedema | Inactive | 28-Feb-2018 | 00000000 | |
| EP-3758702-A4 | Treatment of hereditary angioedema | Inactive | 28-Feb-2018 | 00000000000 | 0 |
| AU-2019227866-A1 | Treatment of hereditary angioedema | Inactive | 28-Feb-2018 | A61P7/10 |
Attune Pharmaceuticals Executive Team (3)
| Name | Title | Board Seat |
|---|---|---|
| Jason Bablak JD | Chief Operating Officer | |
| Ira Kalfus MD | Chief Medical Officer | |
| Andrew McDonald Ph.D | Chief Executive Officer & Board Member |
Attune Pharmaceuticals Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Adam Tomasi Ph.D | Self | Board Member | 000 0000 |
| Andrew McDonald Ph.D | Self | Chief Executive Officer & Board Member | 000 0000 |
| Roderick Wong MD | Self | Board Member | 000 0000 |
Attune Pharmaceuticals Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Boxer Capital | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
| LifeSci Venture Partners | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
| RA Capital Management | Venture Capital | Minority | 000 0000 | 000000 0 |
| RTW Investments | Hedge Fund | Minority | 000 0000 | 000000 0 |
| Tang Capital Management | Venture Capital | Minority | 000 0000 | 000000 0 |
Attune Pharmaceuticals FAQs
-
When was Attune Pharmaceuticals founded?
Attune Pharmaceuticals was founded in 2018.
-
Who is the founder of Attune Pharmaceuticals?
Andrew McDonald Ph.D is the founder of Attune Pharmaceuticals.
-
Who is the CEO of Attune Pharmaceuticals?
Andrew McDonald Ph.D is the CEO of Attune Pharmaceuticals.
-
Where is Attune Pharmaceuticals headquartered?
Attune Pharmaceuticals is headquartered in New York, NY.
-
What industry is Attune Pharmaceuticals in?
Attune Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Attune Pharmaceuticals a private or public company?
Attune Pharmaceuticals is a Private company.
-
What is the current valuation of Attune Pharmaceuticals?
The current valuation of Attune Pharmaceuticals is 00000.
-
What is Attune Pharmaceuticals’s current revenue?
The current revenue for Attune Pharmaceuticals is 000000.
-
How much funding has Attune Pharmaceuticals raised over time?
Attune Pharmaceuticals has raised $30.8M.
-
Who are Attune Pharmaceuticals’s investors?
Boxer Capital, LifeSci Venture Partners, RA Capital Management, RTW Investments, and Tang Capital Management are 5 of 7 investors who have invested in Attune Pharmaceuticals.
-
Who are Attune Pharmaceuticals’s competitors?
Epirium Bio, Morphic Therapeutic, Cour, Immusoft, and JW Therapeutics are some of the 58 competitors of Attune Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
